

1 **Effect of Vitamin D₃ supplementation vs. dietary-hygienic measures on SARS-COV-2**
2 **infection rates in hospital workers with 25-hydroxyvitamin D₃ [25(OH)D₃] levels ≥ 20**
3 **ng/mL**

4
5 **Running head:** SARS-COV-2 infection and vitamin D₃

6 Authors: Maria Elena Romero-Ibarguengoitia ^{a,b}, Dalia Gutiérrez-González ^{a,b}, Carlos Cantú-
7 López ^{a,b}, Miguel Angel Sanz-Sánchez ^{b,c}, Arnulfo González-Cantú* ^{b,d}.

8
9 **Author Affiliations:**

10 ^a Department of Research, *Hospital Clínica Nova*; San Nicolás de los Garza, N.L., Mexico.

11 ^b *Universidad de Monterrey, Vicerrectoría de Ciencias de la Salud, Departamento de Ciencias*
12 *Clínicas*, San Pedro Garza García, N.L. Mexico.

13 ^cGeneral Management, *Hospital Clínica Nova*; San Nicolás de los Garza, N.L., Mexico.

14 ^dDepartment of Endocrinology, *Hospital Clínica Nova*; San Nicolás de los Garza, N.L., Mexico.

15
16 Corresponding Author: Arnulfo González-Cantú, *Hospital Clínica Nova*, Av. del Bosque 139,
17 Cuauhtémoc, 66450 San Nicolás de los Garza, N.L., México. +52- 81- 8865- 5656.
18 drgzccantu@gmail.com

19

20 **Abstract**

21 **Background.** There is scant information on the effect of supplementation with vitamin D₃ in
22 SARS-COV-2 infection cases when patient 25-hydroxyvitamin D₃ [25(OH)D₃] levels are
23 between 20-100ng/mL. Our aim was to evaluate the effect of supplementation with vitamin D₃
24 vs. dietary-hygienic measures on the SARS-COV-2 infection rate in participants with serum
25 25(OH)D₃ levels \geq 20ng/mL. **Methods.** We invited hospital workers with 25(OH)D₃
26 levels between 20-100 ng/mL and no previous SARS-COV-2 infection; they were randomized as
27 follows: treatment options were a) vitamin D₃ supplementation (52,000 IU monthly, G1) or b)
28 dietary-hygienic measures (G2). We conducted a 3- to 6-month follow-up of SARS-COV-2
29 infections. Participants with 25(OH)D₃ levels <20 ng/mL were also analyzed. We divided these
30 latter participants depending on whether they were supplemented (G3) or not (G4). **Results.** We
31 analyzed 198 participants, with an average age of 44.4 (SD 9) years, and 130 (65.7%) were
32 women. G1 had less cases of SARS-COV-2 infection than G2 after a follow-up of 3- to 6-
33 months ($p < 0.05$). There were no differences between G3 and G4 at the 3- and 6-month follow-up
34 cutoff points ($p > 0.05$). Using mixed effect Cox regression analysis in 164 participants that
35 completed six months of follow-up, vitamin D₃ supplementation appeared to act as a protective
36 factor against SARS-COV-2 infection (HR 0.21, $p = 0.008$) in G1 and G2. None of the
37 participants treated with the supplementation doses had serum 25(OH)D₃ levels > 100 ng/mL.
38 **Conclusion.** Vitamin D₃ supplementation in participants with 25(OH)D₃ levels between 20-100
39 ng/mL have a lower rate of SARS-COV-2 infection in comparison with the use of dietary-
40 hygienic measures at six months follow-up.

41

42 **Keywords:** SARS-COV-2, vitamin D₃, supplementation

43 **Introduction**

44 COVID-19 is an infectious disease caused by the newly discovered coronavirus SARS-CoV-2;
45 its clinical spectrum ranges from asymptomatic infection to critical and fatal illness^{1,2} [1,2]. The
46 first case was reported in Wuhan, China, in December 2019, while the first case in Latin
47 America was detected in Brazil in February 2020^{3,4} [3,4]. As of March 13, 2022, approximately
48 458,479,635 cases were confirmed, and 3 million deaths were reported worldwide.
49 Furthermore, 10,712,423,741 vaccine doses have been applied⁵ [5].

50 To date, prevention remains the cornerstone of management to decrease infection rates. In late
51 2020, the authorization of SARS-CoV-2 emergency vaccines led to partial pandemic control.
52 However, further studies will be key to obtain clear evidence on its treatment and prevention⁶
53 [6].

54 There is controversy on the use of vitamin D₃ supplementation in the prevention of SARS-CoV-
55 2⁷ [7]. A meta-analysis concluded that a low serum 25-hydroxyvitamin D₃ [25(OH)D₃] level was
56 significantly associated with a higher risk of SARS-CoV-2 infection⁸ [8]. However, there is
57 limited data on the link between SARS-COV-2 infection and vitamin D₃ supplementation in
58 individuals with normal 25(OH)D₃ levels.

59 The rationale for this study was to establish a relationship between vitamin D₃ supplementation
60 and the incidence of SARS-CoV-2 infection in a prospective study. The target population
61 included health workers at high risk of SARS-COV-2 infection and vitamin D serum values ≥ 20
62 ng/mL.

63 We expected a positive effect of vitamin D supplementation on the immune system (innate and
64 adaptive immunity)^{9,10} [9,10], and that the group who underwent supplementation would
65 develop fewer SARS-COV-2 cases.

66 The study aimed to evaluate the effect of vitamin D₃ supplementation vs. dietary-hygienic
67 measures on the development of SARS-COV-2 infection in participants with serum 25(OH)D₃
68 ≥ 20 ng/mL (primary outcome). Secondly, we compared a group of hospital workers with
69 serum 25(OH)D₃ < 20 ng/mL that could not or had not been supplemented with vitamin D₃.
70 We hypothesized that low serum vitamin D₃ is associated with an increased risk of SARS-COV-
71 2 infection. We believed that we would find a difference in the development of SARS-COV-2 in
72 participants with serum 25(OH)D₃ ≥ 20 ng/mL who received vitamin D₃ supplementation vs.
73 dietary-hygienic measures ¹¹[11].

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89 **Methods and Materials**

90 The study was a prospective, quasi-experimental study that followed the CONSORT guidelines²⁵
91 [21]. It included health workers from a hospital in Northern Mexico, the *Hospital Clínica Nova*
92 (HCN), at a northern latitude of 25°45' and western latitude of 100°17'. This hospital was
93 converted to a COVID-19 Hospital in March 2020. Participant recruitment began in May-August
94 2020, when the initial baseline serum vitamin D level was obtained. Participant follow-up
95 continued from August 2020 through January 2021.

96 The study was conducted per The Code of Ethics of the World Medical Association (Declaration
97 of Helsinki) for experiments in humans. It was also approved by the local IRB of the
98 *Universidad de Monterrey* (Ref. 30062020-a-CN-CI) and registered with the clinical trial
99 number NCT04810949 (first released 23/03/2021). Due to the study's nature, an informed
100 consent form was signed by each participant, and two witnesses. The author, AGC, enrolled the
101 participants and assigned them to each intervention.

102 The inclusion criteria were age between 18 and 65 years old, both genders, absence of infection
103 by SARS-COV-2, influenza H1N1, influenza A or B at the time of serum vitamin D₃
104 determination, absence of infection at any site (bacteria or fungi), and participants had to be
105 hospital workers at the HCN. In addition, participants were excluded if their serum 25(OH)D₃
106 was >100 ng/mL, if they had previously received supplements containing vitamin D₃, and if they
107 were pregnant.

108 Individuals were invited to participate in the study after signing the consent form. They were
109 directed to the laboratory to provide serum samples to determine their levels of 25(OH)D₃. We
110 used the Elecsys total vitamin D test with COBAS 6000 (e601) equipment (Wiesbaden
111 Germany). The CV was 4.1%, the analytic specificity for 25(OH)D₃ was 100%, and the analytic

112 sensibility was established at 4.01ng/mL. Calibration of the equipment was performed by the
113 laboratory staff every time there was a change in the lot, and the calibration curve factor was 1
114 (goal 0.8- 1.2).

115
116 Based on the results, we classified participants into four groups. The first and second groups had
117 25(OH)D₃ >20 ng/mL and they were randomized in a 1:1 ratio; the participants had two
118 treatment options: the first, was supplementation with vitamin D₃ 52,000 IU in a single dose,
119 monthly, for three months (13 tablets of 4,000 UI, G1). The total dose is based on the Endocrine
120 Society's Guidelines^{26,27} [26,27]; however, we decided to administer it every month instead of a
121 daily, since some of this frequency's benefits have been discussed elsewhere²⁸[25]. The second
122 option was treatment based on dietary-hygienic measures (G2), such as sun exposure for at least
123 10 minutes per day between 10:00-18:00 hrs., and foods that were rich in vitamin D₃ and D₂
124 (fish, meat, eggs, milk, mushrooms, and, almonds)^{29,30}[29,30].

125 The third and fourth groups had 25(OH)D₃ levels ≤20 ng/mL. These groups were not part of the
126 randomization process, since we considered that all subjects with vitamin D₃ <20ng/mL should
127 receive vitamin D₃ supplementation³¹ [31], and they were referred to their personal primary care
128 physician (different primary care physician) for treatment and follow-up (G3). Nevertheless, a
129 certain number of participants decided, of their own volition, not to receive vitamin D₃
130 supplementation (G4), but since they were health workers and had a medical record from the
131 same hospital where the study was conducted, we could still follow them over time. Our
132 secondary aim was to also determine the incidence of SARS-COV-2 infection in this group. We,
133 therefore, had 4 groups for comparisons.

134 Variables obtained from the medical record were age, gender, occupation, diabetes mellitus,
135 hypertension, allergies, asthma, smoking history, previous hospitalizations, and BMI.

136 The participants were monitored monthly during follow-up, every month by telephone, and every
137 3 months in a face-to-face interview. We inquired on COVID-19 symptoms (myalgias,
138 hyposmia, cough, malaise and fatigue, nasal congestion, fever, diarrhea, thoracic pain, shaking
139 chills, nausea, and vomiting), and whether they had been diagnosed with SARS-COV-2 infection
140 by serologic or swab tests (PCR). Also, every month patients were asked if they had been
141 consuming food with vitamin D₃ or D₂ using a 24h food recall questionnaire. Serum 25(OH)D₃
142 was measured at baseline and after three months of follow-up.

143 The relative risks that could be present in the different groups were increased serum vitamin D
144 levels (> 100ng /ml) in G1 and decreased vitamin D serum levels < 20ng/mL in G2. The risks in
145 G3 and G4 could not be controlled by the research group.

146 The relative risks that could be present in the different groups were an increase in vitamin D
147 serum levels > 100ng /ml in G1, and decreased vitamin D serum levels < 20ng/mL in G2. The
148 risk in G3 and G4 could not be controlled by the research group.

149

150 **Statistical analysis**

151 Two researchers reviewed the quality control of the database and anonymized it. Normality
152 assumption was evaluated with the Shapiro Wilk test and frequency histograms. Descriptive
153 statistics such as the mean, the standard deviation for quantitative variables, frequencies, and
154 percentages for categorical variables, were computed. Chi-square tests and ANOVA were used
155 to compare the categorical and quantitative data between groups. Kaplan-Meier curves and the
156 Log-rank test were used to evaluate the difference in SARS-COV-2 infection between groups.

157 We conducted a mixed effect Cox regression analysis in the groups with 25(OH)D₃ ≥20 ng/mL
158 and <20 ng/mL, in which the dependent variable was SARS-COV-2 infection at six months. The
159 covariates computed in the model were vitamin D₃ supplementation, age, and gender. The
160 seasonal variation was a random effect. Missing data were handled by complete case analysis.
161 For the simple randomization, we used random number generation with a binomial distribution,
162 and a probability of 50%. The author, AGC, generated the randomization sequence.
163 The statistical programs used were SPSS version 25 (IBM, USA) and R software version 4.0.3
164 (R Core Team, Vienna Austria). The analysis was two-tailed. A p-value < 0.05 was considered
165 statistically significant. The sample size included all hospital workers that agreed to provide
166 serum samples for 25(OH)D₃ testing.

167
168
169
170
171
172
173
174
175
176
177
178
179

180 **Results**

181 Initially, 205 hospital workers were considered for the study; five had to be excluded because
182 they had previously contracted SARS-COV-2, before the study started. Additionally, two
183 individuals in the G1 and G2 withdrew their consent to participate.

184 In the end, 198 participants were analyzed. These participants were distributed in four groups
185 based on their 25(OH)D₃ levels and the type of treatment administered. Group 1 (G1) included
186 participants with 25(OH)D₃ level ≥ 20 ng/mL plus supplementation (52,000IU/month) (n=43).

187 Group 2 (G2) consisted of participants with 25(OH)D₃ level ≥ 20 ng/mL managed with dietary-
188 hygienic measures (n=42). Group 3 (G3) had participants with serum 25(OH)D₃ < 20 ng/mL plus
189 supplementation (90,000IU/month, average dose provided by their treating physician) (n=28).

190 Finally, group 4 (G4) included participants with 25(OH)D₃ < 20 ng/mL, without supplementation
191 (n=85).

192

193 The mean (SD) age in the four groups was 44.4 (9.1) years ($p > 0.05$), with no difference between
194 groups, and 130 were female (65.7%). The three most frequent professions in all the groups
195 were: physician, nurses, and administrative workers, and no difference was established among
196 G1-G4 ($p > 0.05$). There were also no differences in terms of smoking history, Body Mass Index
197 (BMI), allergies, Type 2 diabetes, hypertension, and asthma ($p > 0.05$). Demographic data and
198 medical history of the groups are described in Table 1.

199

200 The mean (SD) serum baseline 25(OH)D₃ levels reported per group were: 27.1 (6.7) ng/mL in
201 G1, 26.6 (5.5) ng/mL in G2, 15.4 (3.4) ng/mL in G3, and 14.9 (3.1) ng/mL in G4, $p < 0.001$.

202 Serum levels of 25(OH)D₃ were again measured after three months of follow-up. The values

203 were as follows: G1 33.8 (7.1) ng/mL, G2 22.4 (6.9) ng/mL, G3 38.2 (8.5) ng/mL and G4 22.1
204 (5.8) ng/mL, $p < 0.001$.

205
206 At the 3-month cutoff, 51 (25.8%) of the 198 workers had developed SARS-COV-2 infection
207 (naïve variant). The distribution of cases by groups was: G2 14 (33%) and G1 3 (7%), $p = 0.002$;
208 G4 27 (32%) and G3 7 (25%), $p > 0.05$. When comparing between the four groups there was a
209 statistical difference, $p = 0.017$.

210
211 One hundred eighty-seven (187) individuals were followed for four months; of these, 56 (29.4%)
212 developed SARS-COV-2 infection (naïve variant). The proportion of SARS-COV-2 infection
213 cases by groups was: G2 14 (34%) and G1 6 (14%), $p = 0.002$; G4 29 (38%), and G3 7 (26%), p
214 $= 0.04$. When comparing between the four groups there was a statistical difference, $p = 0.041$
215 Additionally, we studied 167 workers that completed a 6-month follow-up. Not all participants
216 completed this 6-month follow-up because they were recruited at a later date, the SARS-COV-2
217 vaccination campaign had begun, and we considered that vaccination could affect our results; we
218 therefore completed our study follow-up, and they were not included in this timeline analysis.
219 However, during that period, 56 (33.5%) developed Covid-19 (naïve variant). The number of
220 cases by group was as follows: G2 13 (39%) and G1 5 (13%), $p < 0.001$; G4 29 (40%) and G3 9
221 (37%), $p > 0.05$. When comparing between the four groups there was statistical difference,
222 $p = 0.031$. Figure 1 shows comparisons between G1 vs. G2 and G3 vs G4. The Nursing
223 Department had the highest proportion of SARS-COV-2 infections, although no statistical
224 difference between groups was detected ($p > 0.05$). The most frequently reported symptoms were
225 myalgias and fatigue. A total of 8 (14%) participants were hospitalized during the study, with no

226 statistical difference between groups ($p>0.05$). Only one worker in the G4 group required
227 intubation. There were no deaths in the study. Data on the SARS-COV-2 infections during the 6-
228 month follow-up is presented in Table 2.

229 We conducted a mixed effect Cox regression analysis with the participants who were followed
230 for six months ($n=164$). The final covariates computed in the model were vitamin D₃
231 supplementation, age, and gender. The seasonal variation was a random effect. In the Group \geq
232 20ng/mL 25(OH)D₃, the resulting HR was 0.21 (SE 0.58, $p= 0.008$) for vitamin D₃
233 supplementation; age, 0.97 (SE 0.26, $p=0.25$); and gender, 0.85 (SE 0.49, $p=0.76$). In the Group
234 < 20 ng/mL 25(OH)D₃, the HR was 1.15 (SE 0.39, $p= 0.72$) for vitamin D₃ supplementation;
235 age, 1.001 (SE 0.02, $p=0.94$); and gender, 0.52 (SE 0.48, $p=0.18$). Other covariates that were
236 explored were BMI, Type 2 diabetes, and hypertension, but they were not statistically
237 significant, so they were eliminated from the final models.

238 In the G1 and G3 groups that were supplemented with 52,000 IU/month and 90,000IU for three
239 months, respectively, none of the participants had 25(OH)D₃ levels >100 ng/mL and no adverse
240 events were reported.

241

242

243

244

245

246

247

248

249 Discussion

250 This study demonstrated that vitamin D₃ supplementation for three months led to a decrease in
251 the rate of SARS-COV-2 infection in the group of participants with 25(OH)D₃ levels ≥ 20 ng/mL
252 throughout the 3–6-month follow-up when compared with dietary-hygienic measures.

253 In this study, participants with 25(OH)D₃ levels < 20 ng/mL had a higher rate of SARS-COV-2
254 infection; however, upon comparison of groups (G3 and G4), the supplemented group had less
255 frequent SARS-COV-2 infections at four months of follow-up but not at six months.

256
257 Previous studies, including a metanalysis, revealed an association of low serum 25(OH)D₃
258 levels with SARS-COV-2 infection^{8,12}[8,12]. Another study reported a correlation of this
259 deficiency with an aging population, aside from associated comorbidities such as diabetes
260 mellitus, hypertension, or obesity^{12,13} [12,13]. This suggests that there is an inverse relation
261 between SARS-COV-2 infection and 25(OH)D₃ levels. As mentioned previously, we did find an
262 association between low levels of 25(OH)D₃ and SARS-COV-2 infection; however, when we
263 evaluated the comorbidities, we did not find a difference in participants with comorbidities.
264 Thus, the most important predictor of infection in the regression models was the supplementation
265 with vitamin D₃ and low 25(OH)D₃ values.

266
267 A study conducted in Barcelona demonstrated that participants that had previously received
268 vitamin D for four months were at a decreased risk of acquiring SARS-COV-2 infection (HR =
269 0.95, CI 0.91–0.98), but this was not applicable in individuals on calcifediol¹⁴ [14]. A previous
270 clinical trial conducted in Mexico City included health workers who were randomized to receive
271 either 4000 IU of vitamin D₃ for 30 days or placebo and were followed for 45 days. The results

272 showed that independently of the baseline 25(OH)D₃ (that in the study was mostly deficient), the
273 supplemented group had a lower incidence of SARS-COV-2 infection¹⁵ [15].

274 A study conducted in Veteran patients in the US Defense Department health system, showed an
275 inverse dose-response relationship between continuously increasing 25(OH)D concentrations
276 (from 15 to 60 ng/mL with supplementation), and a parallel decreased probability of requiring
277 COVID-19-related hospitalization¹⁶ [16].

278

279 As previously stated, our study supports the importance of supplementation. Nevertheless, there
280 is still a lack of information to be obtained in clinical trials on SARS-COV-2 management, and
281 on the potential benefit of supplementation with vitamin D₃ in participants with 25(OH)D₃ \geq 20
282 ng/mL to decrease SARS-COV-2 infection risk; therein lies the value of our study in which we
283 also evaluated the effect in this group of participants in a prospectively manner.

284

285 We observed that in our group of participants who followed dietary-hygienic measures, their
286 25(OH)D₃ levels had decreased when measured a second time. This may result from the
287 difficulty among the participants to closely adhere to the recommendations provided by the
288 physician, such as sun exposure, work hours, and diet. Further, it is important to note that the
289 second measurement of 25(OH)D₃ was obtained in the winter season. These factors could
290 explain the increased number of cases of SARS-COV-2 infection and underscore the usefulness
291 of supplementation in the population during this time of the year. Our regression model that
292 adjusted the seasonal variation, reinforce the importance of supplementation.

293

294 Since there is evidence of a greater risk of acquiring a SARS-COV-2 infection and an increase in
295 its severity among participants with 25(OH)D₃ levels <20 ng/mL^{8,17-19}[8,15,17], we considered
296 it would not be ethical to randomize treatment in these groups of participants. They were referred
297 to the primary care physician to initiate supplementation. Unfortunately, despite the treatment
298 options and recommendations, some participants decided not to follow them. However, the
299 supplemented group had a lower incidence of SARS-COV-2 at four months of follow-up but not
300 at six months. We believe that there was an important effect of 3-month supplementation but that
301 was not sustained for six months, so future studies must be conducted were a sustained
302 supplementation is evaluated.

303 From a mechanistic point of view, vitamin D status could also be an index of nitric oxide
304 concentrations induced by solar UVA rays and these may act in concert to potentially prevent the
305 COVID-19-dependent cytokine storm and induced inflammation^{20,21} [20,21]. Also, vitamin D
306 could protect against viral infection through the innate immune response. The induction of
307 cathelicidin and defensins can block viral entry to the cell and suppress viral replication. Another
308 mechanism is by promoting autophagy of the virus, expressing autophagy marker LC3,
309 downregulating the mTOR pathway, promoting Beclin 1 and PI3KC3, and stimulating the
310 formation of autophagosomes to indirectly facilitate viral clearance. Therefore, vitamin D could
311 have an important role in maintaining the balance between autophagy and apoptosis, and thus
312 maximize the antiviral response to infection^{10,22} [10,18].

313 Vitamin D is also a regulator of the adaptive immune response by inducing regulatory T cells
314 that are critical to the induction of immune tolerance, and play a role in preventing the cytokine
315 storm associated with severe respiratory disease caused by viral infections. Vitamin D, via its
316 active metabolite 1,25(OH)₂D, limits the maturation of dendritic cells, and hence, their ability to

317 present antigen to T cells, and change the T cell profile from the proinflammatory Th1 and Th17
318 to Th2 and T regulatory subsets, that inhibit the proinflammatory processes¹⁰ [10].

319
320 Activation of the vitamin D receptor could play a modulatory role to the host responses in the
321 acute respiratory distress syndrome by decreasing cytokines, producing a shift toward amplified
322 adaptive Th2 immune responses, regulating the renin-angiotensin-bradykinin system, modulating
323 neutrophil activity, and maintaining the integrity of the pulmonary epithelial barrier, thus
324 promoting epithelial repair, and decreasing the coagulability and prothrombotic tendency
325 associated with SARS-COV-2 infection²²⁻²⁴ [18-20].

326 One of our study's limitations is the sample size in each group; however, using a formula for the
327 proportion difference between independent groups of 26%, we achieved a power of 86%. Also,
328 some participants did not complete their follow-up at 4- and 6-months because of SARS-COV-2
329 vaccination. We decided to discontinue the study once patients were vaccinated since it could
330 affect our primary outcome. Finally, the study was conducted in only one center and mostly in
331 the winter, so a multicenter study conducted during all seasons is required in the future, and with
332 a greater sample size to confirm the risks and benefits of supplementation in participants with
333 25(OH)D₃ levels <20 ng/mL, in terms of the acquisition of SARS-COV-2 infections.

334
335 The risks of the protocol were minimal since the supplementation of vitamin D₃ at doses of
336 52,000 units per month is not related to any adverse event. Vitamin D hypervitaminosis occurs
337 when serum levels are > 100ng / ml. The administered supplementation dose had a very low risk
338 of causing hypervitaminosis D. Nevertheless, participants' serum levels were monitored at three
339 months as a security measure. Another risk of the study was the possibility of an allergic reaction

340 to any component of the vitamin D₃ presentation formula, but none of the participants developed
341 this condition.

342 **Acknowledgments**

343 We are grateful to Rosalinda González Facio, Laura Patricia Montelongo, and Gerardo Del Río
344 Parra for their assistance in participant follow-up during the trial, and their review of medical
345 records. Likewise, we appreciate the Nursing Department's coordination of appointments.

346 **Author Contribution:**

347 Conceptualization: MERI, AGC, DGG, and MASS. Formal analysis: MERI, AGC, DGG, and
348 CCG. Investigation: MERI, AGC, DGG, MASS, and CCG. Resources: MASS, Writing –
349 original draft: MERI, AGC, DGG, MASS, and CCG. Writing – review and editing: MERI,
350 AGC. Project administration: MERI, DGG, and MASS. Supervision: MERI, AGC, and MASS.
351 Funding acquisition: MASS. All authors contributed to this article and approved the submitted
352 version.

353 **Competing interests:**

354 The author(s) have no conflicts of interest to declare.

355 **Data Availability:**

356 Data are available upon reasonable request to the corresponding author

357 **Funding:**

358 This research received private funding from the hospital. No specific grant was awarded from
359 any funding agency in the public, commercial, or non-profit sectors.

360 **Ethics Statement:**

361 This research project was approved by the local IRB of the *Universidad de Monterrey* (Ref.
362 30062020-a-CN-CI). An informed consent form was obtained from each participant.

363 **Disclosure**

364 The authors have no potential conflicts of interest associated with this study.

365 **Author Approval:** all authors read and approved the final version of the manuscript.

366 **Protocol access:** This study protocol can be reviewed in [Clinicaltrials.gov](https://clinicaltrials.gov).

367

368 **References.**

- 369 1. Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel
370 coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* **395**, 507–513 (2020).
371 2. Jiang, F. *et al.* Review of the Clinical Characteristics of Coronavirus Disease 2019
372 (COVID-19). *J. Gen. Intern. Med.* **35**, 1545–1549 (2020).
373 3. Lopez Santi, R. *et al.* Impact of the Pandemic on NonInfected Cardiometabolic Patients:
374 A Survey in Countries of Latin America—Rationale and Design of the CorCOVID LATAM
375 Study. *CJC Open* **2**, 671–677 (2020).
376 4. Spiteri, G. *et al.* First cases of coronavirus disease 2019 (COVID-19) in the WHO
377 European Region, 24 January to 21 February 2020. *Eurosurveillance* **25**, (2020).
378 5. WHO Coronavirus (COVID-19) Dashboard. <https://covid19.who.int>.
379 6. Mattoli, S. Filling the Gap Until Full Vaccine Deployment in the War on Coronavirus
380 Disease-19. *Infect. Dis. Ther.* **10**, 27–34 (2021).
381 7. Griffin, G. *et al.* Perspective: Vitamin D supplementation prevents rickets and acute
382 respiratory infections when given as daily maintenance but not as intermittent bolus: implications
383 for COVID-19. *Clin. Med.* **21**, e144–e149 (2021).
384 8. Teshome, A., Adane, A., Girma, B. & Mekonnen, Z. A. The Impact of Vitamin D Level
385 on COVID-19 Infection: Systematic Review and Meta-Analysis. *Front. Public Health* **9**, 624559
386 (2021).
387 9. Džopalić, T., Božić-Nedeljković, B. & Jurišić, V. The role of vitamin A and vitamin D in
388 the modulation of the immune response with focus on innate lymphoid cells. *Cent. Eur. J.*
389 *Immunol.* **46**, 264–269 (2021).
390 10. Bilezikian, J. P. *et al.* MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-
391 19. *Eur. J. Endocrinol.* **183**, R133–R147 (2020).
392 11. Office of Dietary Supplements - Vitamin D. [https://ods.od.nih.gov/factsheets/VitaminD-
393 Consumer/](https://ods.od.nih.gov/factsheets/VitaminD-Consumer/).
394 12. Ilie, P. C., Stefanescu, S. & Smith, L. The role of vitamin D in the prevention of
395 coronavirus disease 2019 infection and mortality. *Aging Clin. Exp. Res.* **32**, 1195–1198 (2020).
396 13. Ejaz, H. *et al.* COVID-19 and comorbidities: Deleterious impact on infected patients. *J.*
397 *Infect. Public Health* **13**, 1833–1839 (2020).
398 14. Oristrell, J. *et al.* Vitamin D supplementation and COVID-19 risk: a population-based,
399 cohort study. *J. Endocrinol. Invest.* **45**, 167–179 (2022).
400 15. Villasis-Keever, M. A. *et al.* Efficacy and Safety of Vitamin D Supplementation to
401 Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial. *Arch. Med.*
402 *Res.* **53**, 423–430 (2022).

- 403 16. Seal, K. H. *et al.* Association of Vitamin D Status and COVID-19-Related
404 Hospitalization and Mortality. *J. Gen. Intern. Med.* **37**, 853–861 (2022).
- 405 17. Dror, A. A. *et al.* Pre-infection 25-hydroxyvitamin D3 levels and association with
406 severity of COVID-19 illness. *PLOS ONE* **17**, e0263069 (2022).
- 407 18. Demir, M., Demir, F. & Aygun, H. Vitamin D deficiency is associated with COVID-19
408 positivity and severity of the disease. *J. Med. Virol.* **93**, 2992–2999 (2021).
- 409 19. Chiodini, I. *et al.* Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical
410 Outcomes. *Front. Public Health* **9**, 736665 (2021).
- 411 20. Cherrie, M. *et al.* Ultraviolet A radiation and COVID-19 deaths in the USA with
412 replication studies in England and Italy*. *Br. J. Dermatol.* **185**, 363–370 (2021).
- 413 21. Gorman, S. & Weller, R. B. Investigating the Potential for Ultraviolet Light to Modulate
414 Morbidity and Mortality From COVID-19: A Narrative Review and Update. *Front. Cardiovasc.*
415 *Med.* **7**, 616527 (2020).
- 416 22. Loucera, C. *et al.* Real world evidence of calcifediol or vitamin D prescription and
417 mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients. *Sci.*
418 *Rep.* **11**, 23380 (2021).
- 419 23. Quesada-Gomez, J. M., Entrenas-Castillo, M. & Bouillon, R. Vitamin D receptor
420 stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus
421 SARS-CoV-2 infections: Revised Ms SBMB 2020_166. *J. Steroid Biochem. Mol. Biol.* **202**,
422 105719 (2020).
- 423 24. Martinez-Moreno, J. M. *et al.* Vitamin D modulates tissue factor and protease-activated
424 receptor 2 expression in vascular smooth muscle cells. *FASEB J.* **30**, 1367–1376 (2016).
- 425 25. Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group. CONSORT 2010
426 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ* **340**, c332–
427 c332 (2010).
- 428 26. Holick, M. F. Vitamin D Deficiency. *N. Engl. J. Med.* **357**, 266–281 (2007).
- 429 27. Holick, M. F. *et al.* Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an
430 Endocrine Society Clinical Practice Guideline. *J. Clin. Endocrinol. Metab.* **96**, 1911–1930
431 (2011).
- 432 28. De Niet, S. *et al.* A Randomized Study to Compare a Monthly to a Daily Administration
433 of Vitamin D3 Supplementation. *Nutrients* **10**, 659 (2018).
- 434 29. Crowe, F. L. *et al.* Plasma concentrations of 25-hydroxyvitamin D in meat eaters, fish
435 eaters, vegetarians and vegans: results from the EPIC–Oxford study. *Public Health Nutr.* **14**,
436 340–346 (2011).
- 437 30. Bouillon, R., Verlinden, L. & Verstuyf, A. Is Vitamin D2 Really Bioequivalent to
438 Vitamin D3? *Endocrinology* **157**, 3384–3387 (2016).
- 439 31. Szarpak, L. *et al.* A systematic review and meta-analysis of effect of vitamin D levels on
440 the incidence of COVID-19. *Cardiol. J.* **28**, 647–654 (2021).

441

442

443

444

445 **Figure legends. SARS-COV-2-free survival**

446 Kaplan Meier curves of the SARS-CoV-2 infection rate during the six-month follow-up. The
 447 images compare the 4 groups according to their baseline vitamin status and vitamin D3. Figure
 448 A shows the group with serum 25(OH)D3 ≥ 20 ng/mL. Figure B shows 25(OH)D3 ≤ 20 ng/mL
 449 The lowest rate of SARS-COV-2 infection occurred in the group with vitamin D > 20ng/mL plus
 450 supplementation for three months, 52000IU per month.

451 **Tables**

452 Table1. Demographics and Medical History

Groups n=198	G1	G2	p-value	G3	G4	p-value*
	n= 43	n= 42		n= 28	n= 85	
Female	26 (60)	19 (45)	>0.05	20 (71)	65 (76)	>0.05
Profession						
Physician (%)	15 (35)	16 (38)	>0.05	7(25)	23(27)	>0.05
Nurse (%)	19(44)	15(36)		13(46)	39(46)	
Dentist (%)	1(2)	2(5)		1(4)	7(8)	
Maintenance (%)	2(5)	3(7)		0	1(1)	
Administrative (%)	5(12)	1(2)		4(14)	9(11)	
Nutritionist (%)	0	3(7)		2(7)	2(2)	
Other (%)	1(2)	2(5)		1(4)	4(5)	
Medical History						
Tobacco(%)	1(2)	4(10)	>0.05	2(7)	3(4)	>0.05
BMI (SD)	26.4(5.1)	26.3(3.5)	>0.05	27.8(2.1)	28.2(4.5)	>0.05
Type 2 Diabetes (%)	5(11)	1(2)	>0.05	2(7)	6(7)	>0.05
Allergies (%)	7(16)	7(17)	>0.05	7(25)	20(24)	>0.05
Hypertension (%)	6(14)	3(7.5)	>0.05	5(18)	11(13)	>0.05
Asthma (%)	2(5)	2(5)	>0.05	0	0	

453 *Chi-square test was performed for between-group comparisons. A p-value ≤ 0.05 was
 454 considered statistically significant. Parentheses represent frequency or standard deviation.
 455 Abbreviation: SD: standard deviation; BMI: body mass index; G1: 25(OH)D3 ≥ 20 ng/mL with

456 supplementation; G2: 25(OH)D3 \geq 20 ng/mL without supplementation; G3: 25(OH)D3 <20
 457 ng/mL with supplementation; G4 25(OH)D3 <20 ng/mL without supplementation.


458
 459 Table 2. SARS-COV-2 infection at 6-month follow-up

n=167	G1 (n=38)	G2 (n=33)	p- value	G3 (n=24)	G4 (n=72)	p-value
SARS-COV-2	5 (13)	13 (39)	0.01	9 (37)	29 (40)	>0.05
Physician (%)	2(15)	3(23)	>0.05	2(22)	5(17)	>0.05
Nurse(%)	2(11)	8(61)	0.003	6(67)	17(59)	>0.05
Dentist (%)	0	0		0	3(10)	
Administrative (%)	1(20)	1(100)	>0.05	0	3(10)	
Nutritionist (%)	0	1(33.)		1(11)	1(3)	>0.05
SARS-COV-2 associated symptoms						
Dry cough (%)	0(0)	0(0)		2(22)	5(17)	>0.05
Fatigue (%)	2(40%)	1(7.7%)	>0.05	4(44)	4(14)	0.049
Sore throat (%)	1(20%)	0		1(11)	5(17)	>0.05
Nasal congestion (%)	1(20%)	1(7.7%)	>0.05	0	2(7)	
Fever (%)	1(20%)	2(15.4%)	>0.05	1(11)	2(7)	>0.05
Myalgias (%)	4(80)	2(8)	0.009	4(44)	4(13.8%)	0.049
Diarrhea (%)	1(20)	1(8)	>0.05	1(11)	0	
Chest pain (%)	1(20)	0		0	2(7)	
Shaking chills (%)	1(20)	0		1(11)	0	
Nausea (%)	1(20)	0		0	0	
Hyposmia (%)	0	1(8)			0	
Hospitalizations (%)	2 (40)	1 (8)	>0.05	3 (33)	2 (7)	0.04
Intubations (%)	0 (0)	0 (0)		0	1 (3)	
Reservoir mask (%)	1(20)	0(0)		0	0	
Oxygen via nasal prongs (%)	0 (0)	0 (0)		0	1 (3)	
Pneumonia (%)	3(60)	1(7.7)	0.017	1(11)	2(7)	>0.05

460 A p-value \leq 0.05 was considered statistically significant. Abbreviation: SD: standard deviation; G1:
 461 25(OH)D3 \geq 20 ng/mL with supplementation; G2: 25(OH)D3 \geq 20 ng/mL without supplementation;
 462 G3: 25(OH)D3 <20 ng/mL with supplementation; G4: 25(OH)D3 <20 ng/mL without supplementation.
 463 Parentheses represent frequency or standard deviation

A

— 25(OH)D3 ... 20 ng/ml with supplementation — 25(OH)D3 ... 20 ng/ml without supplementation

**B**

— 25(OH)D3 < 20 ng/ml with supplementation — 25(OH)D3 < 20 ng/ml without supplementation

